The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2019 | Integrated sequencing utilized in a timely and impactful manner in AML/MDS
Charles Mullighan, MBBS, MD, St. Jude Children’s Hospital, Memphis, TN, discusses the late-breaking work from his group in collaboration with the Munich Leukemia Laboratory. He explains how the integrated transcriptomic and genomic sequencing of driver mutations in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) has identified prognostic constellations, and highlights the importance of the work – showing that this approach can be utlilized in a timely and impactful manner. This interview was recorded at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
